Probleme bei der Anwendung von Plasmafraktionen

• LITERATUR

• 1 Allain J. T., Verroust F., Soulier J. P. In vitro and in vivo characterization of factor-VIII preparations. Vox Sang. 1980; 38: 68.
• 2 Alter H. J., Barker L. F., Fiedler H., Frey-Wettstein M., Gitnik G. L., Green- walt T. J., Prince A. M., Reesink H. W., Reinicke V., Seeff L. B., Wright E. C., Zuckerman A. J. International Forum: How fre quent is posttransfusion hepatitis after the introduction of 3rd generation donor screening for hepatitis B? What is its'probable nature?. Vox Sang 1977; 32: 346.
• 3 Alving B. M., Hojima Y., Pisano J. J., Mason B. L., Buckingham jr. R. E., Mo-zen M. M., Finlayson J. S. Hypotension associated with prekallikrein activator (Hageman-Fac-tor fragments) in plasma protein fraction. New Engl. J. Med. 1978; 299: 66.
• 4 Bergmann H. Plastikmaterial und Glas in der Blutkonservierung. Münchn. Med. Wschr. 1972; 114: 2209.
• 5 Bland J. H. L., Laver M. B., Lowenstein E. Hypotension due to 5 per cent plasma protein fraction. New Engl. J. Med. 1972; 286: 109.
• 6 Blauhut B., Bergmann H., Scheid I., Vinazzer H. Erfahrungen mit der Dauersubstitution von Haemophilen in Oberösterreich. Forschg. Erg. Transf. Med. Immun-haematol. 1980; 6: 63.
• 7 Bütler R. Epidemiologische Aspekte der Hepatitis bei Hämophilen. Forsch. Erg. Transf. Med. Immunhaematol. 1977; 4: 63.
• 8 Chandra S., Brummelhuis H. G. J. Prothrombin complex concentrates for clinical use. Vox Sang. 1981; 41: 257.
• 9 Combridge B. S., Wesley E. D. Plasma protein fraction: The disappearance of kinin from the solution on storage. Transfusion 1979; 19: 599.
• 10 Frey R., Hutschenreuter K., Ahne-feld F. W., Steinbereithner K. Vorsichtsmaßnahmen bei der Anwendung kolloidaler Volumenersatzmittel. Anaesthesist 1975; 24: 378.
• 11 Garfield M. D., Ershler W. B., Maki D. G. Malaria transmission by platelet concentrate transfusion. J. Am. Med. Ass. 1978; 240: 2285.
• 12 Haas R. Epidemiologie und Bluttransfusion aus virologischer Sicht. Forsch. Erg. Transf. Med. Immunhaemat. 1975; 2 II 491.
• 13 Hardy P. H. The spirochetes. In Davis B. D. (ed.) Microbiology 2nd ed. Harper and Row; Hagerstown: 1973
• 14 Harrison G. A., Robinson M., Sta-cey R. V. Hypotensive effects of stable plasma protein solution (S. P.P.S.). A preliminary communication. Med. J. Aust. 1971; 2: 1040.
• 15 Hoofnagle J. H., Barker L. F., Thiel J., Gerety R. J. Hepatitis B virus and hepatitis B surface antigen in human albumin products. Transfusion 1976; 16: 141.
• 16 Hoofnagle J. H., Gerety R. J., Thiel J., Barker L. F. The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J. Lab. clin. Med. 1976; 88: 102.
• 17 Hoofnagle J. H., Seeff L. B., Buskell Bales Z., Zimmermann H. J. Veterans Administration Hepatitis Cooperative Study Group: Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. New Engl. J. Med. 1978; 298: 1379.
• 18 Hossli G. Probleme der Massivtransfusion. »Anaesthesia 74«, Dresden 1974; 18 (21) 11..
• 19 Ishizaka K., Ishizaka T., Hornbrook M. M. Physicochemical properties of reaginic anti-body. IV. Presence of a unique immunoglobulin as carrier of reaginic activity. J. Immunol. 1966; 97: 75.
• 20 Izaka K., Tsutsui E., Mima Y., Hasega-wa E. A bradykinin-like substance in heat treated human plasma protein solution. Transfusion 1974; 14: 242.
• 21 Jaeger R. J., Rubin R. J. Plasticizers from plastic devices: extraction. metabolism and accumulation by biological systems. Science 1970; 170: 460.
• 22 Johansson S. G. O. Raised levels of a new immunoglobulin (IgNd) in asthma. Lancet 1967; 11: 51.
• 23 Kacaki J., Wolters G., Kuijpers L., Stulemeyer S. Results of a multicentre clinical trial of the solidphase enzyme immunoassay for hepatitis B surface antigen. Vox Sang. 1978; 35: 65.
• 24 Katchaki J. N. R., Brouwer T., Siem H. Anti-HBc and blood infectivity. New Engl. J. Med. 1978; 298: 1421.
• 25 Kernoff P. B. A., Bowell P. J. Gm types and antibodies in multi-transfused haemophiliacs. Br. J. Haemat. 1973; 24: 443.
• 26 Kevy S. V. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 248.
• 27 Knierim F., Rubinstein P. The detection of Chagas disease. A rapid haemagglutina-tion test for special use in blood banks and epidemiological studies. Vox Sang. 1970; 15: 280.
• 28 Kotitschke R., Stephan W. Antigen-to-activity ratio of factors II and IX in PPSB concentrates. Haemostasis 1981 10 Suppl. 1
• 29 Kuwahara S. S. Prekallikrein activator (Hageman factor fragment) in human plasma fractions. Transfusion 1980; 20: 433.
• 30 Kuwahara S. S., Calera F., Terry E. S. Distribution of polybrominated biphenyls (PBB) among fractions derived from contaminated human plasma. Transfusion 1980; 20: 229.
• 31 Lindner A., Charra B., Sherrard D. J., Scribner B. H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl. J. Med. 1974; 290: 697.
• 32 Liotta I. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 249.
• 33 Maider M. J., Shulman N. R. Major surgery in classic hemophilia using Fraction I. Am. J. Med. 1966; 41: 56.
• 34 Marley P. B., Gilbo C. M. Temperature sensitivity within the pasteurization temperature range of prekallikrein activator in stable plasma protein solution (SPPS). Transfusion 1981; 21: 320.
• 35 McMillan C. W., Diamond L. K., Surgenor D. M. A treatment of classic hemophilia. New Engl. J. Med. 1961; 265: 224.
• 36 Meslet B. J. Y. Anémie hémolytique secondaire au traitement substitutif chez les hémophiles A. Thèse Paris 1975
• 37 Nair P. P. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its com-ponents and derivatives? Vox Sang. 1978; 34: 251.
• 38 Newcombe T. F., Walston M. E. Elective surgery in hemophilia. II. Hematologic control. J. Am. Med. Ass. 1963; 185: 628.
• 39 Ng P. K., Fournel M. A., Lundblad J. L. Plasma protein fraction. Product improvement studies. Transfusion 1981; 21: 682.
• 40 Ohlmeier H., Dahmen E., Hoppe I. Hepatitisrisiko von humanen Gerinnungspräparaten aus gepoolten Plasmen. Ergebnisse einer Prospektivstudie. Dtsch. med. Wschr. 1978; 205: 1700.
• 41 Ohyama T. Effects of phthalate esters on the respiration of rat liver mitochondria. J. Biochem. 1976; 79: 153.
• 42 Orringer E. P., Koury M. J., Blatt P. M., Roberts H. R. Hemolysis caused by factor VIII concentrates. Arch. intern. Med. 1976; 136: 1018.
• 43 Papaevangelou G. J. Post-transfusion hepatitis: European perspective and prophylaxis. Bibl. Haemat. 1980; 46: 15.
• 44 Peck C. C., Zuck T. F. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 252.
• 45 Prager D., Djerassi I., Eyster M. E., Gill F. M., Kajani N. K., Lewis J. H., Lusch C., Rice S., Shapiro S. S. Pennsylvania state-wide hemophilia program: Summary of immediate reactions with the use of factor VIII and factor IX concentrate. Blood 1979; 53: 1012.
• 46 Preuner R. Allergische. blutgruppenunabhängige Transfusionsstörungen. Bibl. Haemat. 1956; 5: 8.
• 47 Prince A. M. Use of hepatitis B immune globulin: Reassessment needed. New Engl. J. Med. 299: 198 1978;
• 48 Pruggmayer D., Stephan W. Gas chromatographic trace analysis of ß-propiolacto-ne in sterilized serum proteins. Vox. Sang. 1976; 31: 191.
• 49 Rosati L. A., Barnes B., Oberman H. A., Premier J. A. Hemolytic anemia due to anti-A and anti-B in concentrated antihemophilic factor preparations. Arch. intern. Med. 1970; 130: 139.
• 50 Rubin R. J., Schiffer C. A. Fate in humans of the plasticizer. di-2-ethylhexyl phthalate arising from transfusion of platelets stored in vinyl plastic bags. Transfusion 1976; 16: 330.
• 51 Seeff L. B., Hoofnagle J. Acute and chronic liver disease in hemophilia. Proceedings of a conference, Bethesda, March 1976. DHEW-Publ.; (NIH): 77-1089 55.
• 52 Seeler R. A. Hemolysis due to anti-A and anti-B in factor VIII preparations. Arch, intern. Med. 132: 101 1972;
• 53 Seeler R. A., Telischi M., Langehen-nig P. L., Ashenhurst J. B. Comparison of anti-A and anti-B titers in factor VIII and IX concentrates. J. Pediat. 1976; 89: 87.
• 54 Sobeslavsky O. Prevalence of markers of hepatitis B virus infection in various countries: A WHO collaborative study. Bull. WHO 1980; 58: 621.
• 55 Stampfli K. Posttransfusionelle Hepatiti-den mit letalem Verlauf. Schweiz. med. Wschr. 1967; 97: 1487.
• 56 Stephan W., Kotitschke R. Prothrombin-komplex-Konzentrat aus kaltsterilisiertem Plasma. Forsch. Erg. Trans. Med. Immun-haematol. 1977; 4: 72.
• 57 Stephan W., Kotitschke R., Prince A. M., Brotman B. Long term tolerance and recovery of ß-propiolactone/ultraviolet treated PPSB in shimpanzees. Thrombos. Haemat. 1981; 46: 511.
• 58 Tabor E., Aronson D. L., Gerety R. J. Removal of hepatitis B virus infectivity from factor IX complex by hepatitis B immune globulin. Lancet 1980; 2: 68.
• 59 Tamagnini G. P., Dormandy K. M., Ellis D., Maycock d'A W. Factor VIII concentrate in haemophilia. Lancet 1975; 2: 188.
• 60 Trepo C., Hantz O., Jacquier M. F., Nemoz G., Cappel R., Trepo D. Different fates of hepatitis B virus markers during plasma fractionation. A clue to the infectivity of blood derivatives. Vox Sang. 1978; 35: 143.
• 61 Valeri C. R., Contreras T. J., Feingold H., Sheibley R. H., Jaeger R. I. Accumulation of di-2-ethylhexyl phthalate (DEHP) in whole blood. platelet concentrates and platelet-poor plasma. I. Effect of DEHP on platelet survival and function. Envir. Hlth. Perspect. Exp. Issue 1973; 3: 103.
• 62 Weil M. H., Shubin H. The »VIP« approach to the bedside management of shock. In Weil M. H. H. Shubin: Critical Care Medicine, Current Principles and Practice pp Harper and Row, Ha-gerstown, MD.; New York, San Francisco, London: 1976: 90-98
• 63 Wickerhauser M., Mercer J. E., Eckenrode J. W. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor. Vox Sang. 1978; 35: 18.
• 64 Wyke R. J., Thornton A., Portmann B., Zuckerman A. J., Tsiquaye K. N., White Y., Das P. K., Williams R. Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet 1979; 1: 520.